Healthcare

Saint Therese To Transition Its New Hope Senior Community to New Ownership

Transition will be final on August 1, 2024 SAINT LOUIS PARK, MN / ACCESSWIRE / June 4, 2024 / After…

7 months ago

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to…

7 months ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company…

7 months ago

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create…

7 months ago

Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary

PALO ALTO, Calif. and NEEDHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a pioneering biotechnology company focused on…

7 months ago

American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting

AON physicians and leaders present their latest cancer findings with fellow thought leaders at the annual conference. American Oncology Network…

7 months ago

Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),…

7 months ago

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to…

7 months ago

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

- In Cohort 5 of PROPEL 2 (0.25 mg/kg/day), oral treatment with infigratinib resulted in a statistically significant and sustained…

7 months ago

FendX Announces Fourth Real-World Testing Site for REPELWRAP(TM) Film with Draganfly Inc.

Nanotechnology performance from testing will provide insights to continue to advance towards commercial productionOakville, Ontario--(Newsfile Corp. - June 4, 2024)…

7 months ago